Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

NCT ID: NCT04863248

Last Updated: 2023-04-14

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-30
• Study Completion Date: 2022-02-02

Brief Summary

This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with metastatic NSCLC treated in the 2nd or 3rd line setting.

Detailed Description

Patients must have documented disease progression during or after one or two lines of systemic therapy for recurrent or metastatic NSCLC. Prior treatment must have included, either in the same line or as separate lines of therapy: 1) a maximum of 1 line of platinum-containing chemotherapy for recurrent/metastatic disease and 2) a maximum of 1 line of a locally approved/authorized programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) containing regimen for recurrent/metastatic disease.

Patients will be randomly assigned (1:1) to receive trilaciclib or placebo intravenously (IV) prior to docetaxel on Day 1 of each 21-day cycle.

The study will include a screening phase, a treatment phase and a survival follow-up phase. The patient may continue to receive treatment on study until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever occurs first.

This study was terminated by the Sponsor for non-safety reasons. At the time of study termination, 10 patients had been screened, 7 were randomized, and 2 of the 7 had discontinued from the study. In addition, it was decided that there would be no statistical analyses of the efficacy or safety data due to the limited number of patients treated (N=7).

Conditions

Metastatic Non-Small Cell Lung Cancer; NSCLC; Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

trilaciclib + docetaxel

Patients will receive trilaciclib administered IV prior to docetaxel administered IV on Day 1 of each 21-day cycle.

Group Type: EXPERIMENTAL

Trilaciclib

Intervention Type: DRUG

Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.

Docetaxel

Intervention Type: DRUG

Docetaxel administered IV on Day 1 of each 21-day cycle.

placebo + docetaxel

Patients will receive placebo administered IV prior to docetaxel administered IV on Day 1 of each 21-day cycle.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.

Docetaxel

Intervention Type: DRUG

Docetaxel administered IV on Day 1 of each 21-day cycle.

Interventions

Trilaciclib

Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.

Intervention Type: DRUG

Placebo

Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.

Intervention Type: DRUG

Docetaxel

Docetaxel administered IV on Day 1 of each 21-day cycle.

Intervention Type: DRUG

Other Intervention Names

COSELA; G1T28; 0.9% sodium chloride; 5% Dextrose in water (D5W); Taxotere; Docefrez

Eligibility Criteria

Inclusion Criteria

• Age ≥18 years of age at the time of signing the informed consent.
• Histologically or cytologically confirmed metastatic NSCLC (squamous or nonsquamous) with no known actionable driver mutations (eg, EGFR, ROS1, ALK).

1. Patients must have had documented disease progression during or after 1 or 2 lines of systemic treatment for recurrent or metastatic disease.

2. Two components of treatment must have been received in the same line or as separate lines of therapy: (i) a maximum of 1 line of platinum-containing chemotherapy regimen for recurrent/metastatic disease, and (ii) a maximum of 1 line of a locally approved/authorized PD-1/PD-L1 mAb containing regimen for recurrent/metastatic disease.

3. Maintenance therapy following platinum doublet-based chemotherapy is not considered as a separate line of therapy. Maintenance therapy is defined as therapy given within 42 days after the last dose of platinum-based chemotherapy in patients with ongoing clinical benefit (complete response [CR], partial response [PR] or stable disease [SD]).

• Measurable or non-measurable disease per RECIST v1.1.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
• A formalin-fixed paraffin-embedded (FFPE) tumor specimen (from archival or fresh biopsy) with an associated pathology report documenting NSCLC must be available to send to the Sponsor, within the specified timeframe, for planned retrospective biomarker analyses.
• Adequate organ function defined by the normal laboratory values.

Exclusion Criteria

• Prior therapy with docetaxel.
• Any contraindication to the administration of docetaxel at the discretion of the investigator.
• Mixed NSCLC/SCLC, or lung tumors whose predominant histology is sarcomatoid, or neuroendocrine.
• Any chemotherapy, immunotherapy, biologic, investigational, or hormonal therapy for cancer treatment (except for adjuvant hormonal therapy for breast cancer or prostate cancer defined as M0 disease or prostate-specific antigen (PSA) persistence/recurrence without metastatic disease) within 3 weeks prior to the first dose of trilaciclib/placebo.
• Any radiotherapy within 2 weeks prior to the first dose of trilaciclib/placebo.
• Presence of central nervous system (CNS) metastases requiring immediate treatment with radiation therapy or steroids (i.e., patient must be off steroids administered for brain metastases for at least 14 days prior to the first dose of trilaciclib/placebo).
• Presence of leptomeningeal disease.
• Significant third-space fluid retention (eg, ascites or pleural effusion) not amenable to required repeat drainage.
• QT corrected using Fridericia's formula (QTcF) interval >480 msec at screening (confirmed on repeat). For patients with ventricular pacemakers, QTcF >500 msec.
• Symptomatic peripheral neuropathy.
• History of interstitial lung disease (ILD).
• Prior allogeneic or autologous hematopoietic stem cell or bone marrow transplantation.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

G1 Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Contact

Role: STUDY_DIRECTOR

G1 Therapeutics, Inc.

Locations

Ironwood Cancer & Research Centers

Phoenix, Arizona, United States

Valkyrie Clinical Trials

Los Angeles, California, United States

Desert Hematology Oncology Medical Group, Inc

Rancho Mirage, California, United States

Innovative Clinical Research Institute - Oncology

Whittier, California, United States

Mid-Florida Hematology Oncology

Orange City, Florida, United States

Indiana University Health Goshen Cancer Center

Goshen, Indiana, United States

St. Louis Cancer Care, LLP

Bridgeton, Missouri, United States

Summit Medical Group

Florham Park, New Jersey, United States

Regional Cancer Car Associates, LLC

Little Silver, New Jersey, United States

Gettysburg Cancer Center

Gettysburg, Pennsylvania, United States

University of Tennessee Medical Center

Knoxville, Tennessee, United States

Millennium Oncology

Houston, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

2021-000186-32

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

G1T28-210

Identifier Type: -

Identifier Source: org_study_id